Hims & Hers Surges on Novo Nordisk Deal, Insiders Sell

NEW YORK, July 20 —

Hims & Hers Health stock posted what multiple news sources described as its best single session in company history, jumping 14% on reports of a Novo Nordisk partnership and incinerating an estimated $546 million in short positions along the way. The notable footnote: the company's CFO, CTO, and CMO had spent the preceding five weeks selling shares in the open market at prices between $31.50 and $36.49.

The Squeeze

Short squeezes have a self-reinforcing structure: a fast move on headline news forces short sellers to buy back shares to cover mounting losses, which pushes the stock higher still, which triggers more covering. At $546 million in burned positions, the HIMS session qualifies as a significant example. The catalyst, per multiple news outlets, was a reported partnership with Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy. The framing is obvious: a direct-to-consumer telehealth platform gaining a formal supply or distribution relationship with the dominant GLP-1 manufacturer would represent a different kind of business than HIMS has been operating. Barclays added momentum with a note arguing the market is underestimating the opportunity from HIMS new products, which pointed investors toward the same conclusion ahead of the day's move.

Selling Season

In the five weeks before the surge, three senior HIMS executives filed Form 4 disclosures reporting open-market sales. CTO Mohamed Elshenawy sold 30,040 shares at $31.50 on June 17 for approximately $946,000. CMO Patrick Harrison Carroll sold 23,726 shares at $35.00 on June 18 for approximately $830,000. CFO Oluyemi Okupe made two transactions: 18,197 shares at $34.03 on June 22 for approximately $619,000, and 7,163 shares at $36.49 on July 6 for approximately $261,000. The pattern runs across the finance, technology, and medical functions of the senior team within a compressed window.

Form 4 filings confirm the transaction mechanics but do not specify whether these sales were executed under pre-arranged 10b5-1 trading plans. Such plans, which executives establish in advance to insulate themselves from insider trading concerns, would make the timing coincidental rather than informative. The available disclosures leave that question open, which means investors are looking at a pattern without a stated explanation for it.

The 8-K Trail

Two SEC filings bracket the reported deal. A June 2 8-K disclosed entry into a Material Definitive Agreement, the creation of a Material Direct Financial Obligation, and other events. A July 1 8-K disclosed another Material Definitive Agreement and a new financial obligation. The July 1 filing lands close enough to the news reports of a Novo Nordisk partnership to be consistent with that timeline. Neither filing names Novo Nordisk specifically, and the commercial terms of the reported arrangement — revenue split, exclusivity scope, volume commitments — have not appeared in any public SEC disclosure reviewed for this piece.

What Changes the Picture

A confirmed Novo Nordisk partnership with actual commercial terms would represent a structural shift for a telehealth platform that built its GLP-1 business on compounded access. A formal arrangement with the branded-drug manufacturer introduces a different kind of distribution moat and, potentially, a different cost structure. Barclays' argument that the market underestimates the product opportunity fits that thesis.

The neutral case rests on what has not been disclosed. Deal terms remain unconfirmed at the SEC filing level, the insider selling pattern in the $31 to $36 range is unresolved without knowing whether 10b5-1 plans were in place, and the stock's best day ever may be pricing in a partnership whose specifics no outside investor has yet seen. The next material checkpoint is a public filing that either confirms the Novo Nordisk relationship with contractual detail or leaves the market trading on continued speculation.

Run the free Hims & Hers Health, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

What caused HIMS stock to surge today?

Multiple news outlets reported a partnership with Novo Nordisk as the primary catalyst for a 14% single-session jump described as the stock's best day ever. Barclays also released a note arguing the market underestimates the opportunity from HIMS new products, adding momentum to the move.

How much did short sellers lose on HIMS stock?

News reports estimated roughly $546 million in short positions were burned during the surge session. Short squeezes occur when rapid price moves force short sellers to buy back shares to cover losses, which can accelerate the rally as covering demand compounds on itself.

Did HIMS insiders sell shares before the Novo Nordisk news?

Form 4 filings show the CFO, CTO, and CMO made open-market sales between June 17 and July 6, the five weeks before the surge. Proceeds across the three executives totaled approximately $2.66 million at prices from $31.50 to $36.49. The filings do not confirm whether these were pre-planned under 10b5-1 trading programs.

Is the HIMS Novo Nordisk deal confirmed by SEC filings?

The reported partnership has not been confirmed in a named SEC disclosure. HIMS filed 8-Ks on June 2 and July 1, 2026 disclosing Material Definitive Agreements, but neither filing names Novo Nordisk or discloses commercial terms of any reported arrangement.

What is the outlook for HIMS stock after the surge?

The reported Novo Nordisk partnership and the Barclays note are positive signals, but the outlook carries uncertainty. Deal terms remain unconfirmed at the SEC level, and the C-suite selling pattern that preceded the rally is an open question until investors know whether those transactions were pre-scheduled. A formal filing with specific commercial details is the next meaningful checkpoint.